Announced acquisition of Sanara MedTech, creating a top regenerative medicine company with a strong surgical focus. Q2 saw sequential recovery in wound care and 15% YoY growth in surgical, with full-year guidance reiterated. Combined 2027 revenue expected to exceed $400 million with 20%+ EBITDA margin.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.